Cargando…

PB2215: HYDROXYUREA-INDUCED CUTANEUS ADVERSE EVENTS IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA: A SINGLE-CENTER EXPERIENCE

Detalles Bibliográficos
Autores principales:	Peña, Amaia Lopez, Miguelez, Marta Sofia Ordas, Lefler, Carmen Rodriguez, Membreño, Jhossyuriel Obregon, Resina, Rita Gonzalez, Cuezva, Laura Fernandez, Gutierrez, Mar Herrero, Gomez, Pablo Estuardo Lopez, Bahillo, Leire Etxebarria, Martínez, Laura Villarroya, Gil, Rafael Monleon, Beltran, Pilar Delgado, Caballero Navarro, Gonzalo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428839/ http://dx.doi.org/10.1097/01.HS9.0000975608.89382.f6

Ejemplares similares

PB2022: ELTROMBOPAG IN MYELODYSPLASTIC SYNDROME AND CHRONIC MYELOMONOCYTIC LEUKEMIA: A SINGLE-CENTER EXPERIENCE
por: Peña, Amaia Lopez, et al.
Publicado: (2023)

Chronic Cutaneus Mucormycosis in an Immunocompetent Female
por: Heydari, Ali Akbar, et al.
Publicado: (2013)

Unusual Presentation of naevus Lipomatosus Cutaneus Superficialis
por: Pai, Varadraj Vasant, et al.
Publicado: (2013)

TDV-2215
Publicado: (1980)

An Ulceronecrotic Foot Lesion in a Patient with Essential Thrombocythemia: Successful Treatment with Hydroxyurea
por: Kato, Tokue, et al.
Publicado: (2012)

Cutaneus myxosporidiasis in the Australian green tree frog (Litoria caerulea)
por: Szczepaniak, Klaudiusz, et al.
Publicado: (2010)

Next Generation Sequencing Approach in a Prenatal Case of Cardio-Facio-Cutaneus Syndrome
por: Mucciolo, Mafalda, et al.
Publicado: (2016)

Successful Management of Hydroxyurea-induced Leg Ulcers in Essential Thrombocythemia: Report of 3 Cases
por: Rahal, Jihane Abou, et al.
Publicado: (2013)

69 Severe Cutaneus Drug Reactions: Description of a Serie Cases
por: Fernandes, Fátima, et al.
Publicado: (2012)

Diffuse bullous cutaneus mastocytosis in an indigenous child of the Amazon Region of Ecuador
por: Ruiz, Gabriela Varsovia Acosta, et al.
Publicado: (2015)

Prognostic value of modified criteria for hydroxyurea resistance or intolerance in patients with high‐risk essential thrombocythemia
por: Park, Young Hoon, et al.
Publicado: (2023)

Rapid and robust reversion to essential thrombocythemia on treatment with Decitabine in a case of hydroxyurea‐induced t‐MDS/AML
por: Horton, Joshua D., et al.
Publicado: (2015)

A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia
por: Mascarenhas, John, et al.
Publicado: (2022)

Cutaneus cancers in elderly Medical treatment of actinic keratosis and superficial coutaneus cancers: imiquimod
por: Dastoli, M N
Publicado: (2010)

P1046: TREATMENT COMPARISON OF HYDROXYUREA VS RUXOLITINIB IN ESSENTIAL THROMBOCYTHEMIA (ET): A MATCHED COHORT ANALYSIS
por: Grunwald, Michael, et al.
Publicado: (2023)

Acquired Melanonychia in Chilean Patients with Essential Thrombocythemia Treated with Hydroxyurea: A Report of 7 Clinical Cases and Review of the Literature
por: Murray, Nigel P., et al.
Publicado: (2013)

2215 The value of storytelling in community stakeholder feedback for clinical and translational research
por: Novak, Laurie L., et al.
Publicado: (2018)

Long-term and low-dose of busulfan is a safe and effective second-line treatment in elderly patients with essential thrombocythemia resistant or intolerant to hydroxyurea
por: Renso, Rossella, et al.
Publicado: (2018)

S168: PELABRESIB (CPI-0610) MONOTHERAPY IN PATIENTS WITH HIGH-RISK ESSENTIAL THROMBOCYTHEMIA REFRACTORY OR INTOLERANT TO HYDROXYUREA: PRELIMINARY RESULTS FROM MANIFEST STUDY
por: Passamonti, Francesco, et al.
Publicado: (2023)

HBV Integration-mediated Cell Apoptosis in HepG2.2.15
por: Hu, Xiaoge, et al.
Publicado: (2019)

Essential thrombocythemia
por: Brière, Jean B
Publicado: (2007)

Management of thrombocythemia
por: Gowin, Krisstina, et al.
Publicado: (2014)

PReS-FINAL-2215: Genotype-phenotype correlations in children with Familial Mediterranean Fever in Germany
por: Gohar, F, et al.
Publicado: (2013)

PB2215: GLOBAL EPIDEMIOLOGY OF SICKLE CELL DISEASE: A SYSTEMATIC LITERATURE REVIEW
por: Colombatti, R., et al.
Publicado: (2022)

The effect of desacetyluvaricin on the expression of TLR4 and P53 protein in Hepg 2.2.15
por: He, Hai Bin, et al.
Publicado: (2011)

Dihydroartemisinin inhibits HepG2.2.15 proliferation by inducing cellular senescence and autophagy
por: Zou, Jiang, et al.
Publicado: (2019)

2215: Neuropilin-2 is expressed by activated alveolar macrophages and negatively regulates allergic airway inflammation
por: Moran, Timothy P., et al.
Publicado: (2018)

Ruxolitinib for essential thrombocythemia?
por: Bose, Prithviraj, et al.
Publicado: (2017)

2215. Diarrheal Illness as a Risk Factor for Subsequent Respiratory Infection Among Women and Infants in Nepal
por: Newman, Kira L, et al.
Publicado: (2019)

Small protein Cgl2215 enhances phenolic tolerance by promoting MytA activity in Corynebacterium glutamicum
por: Gu, Huawei, et al.
Publicado: (2022)

Emerging treatments for essential thrombocythemia
por: Okoli, Steven, et al.
Publicado: (2011)

Thromboembolic complication in Essential Thrombocythemia
por: Mozaheb, Zahra
Publicado: (2012)

Sweet's syndrome with idiopathic thrombocythemia
por: Kaszewski, Sebastian, et al.
Publicado: (2014)

Essential thrombocythemia: Busulphan revisited
por: Koduri, Prasad R.
Publicado: (2016)

Ruxolitinib for the Treatment of Essential Thrombocythemia
por: Gunawan, Arief, et al.
Publicado: (2018)

Essential Thrombocythemia in Children and Adolescents
por: Putti, Maria Caterina, et al.
Publicado: (2021)

Mutations and thrombosis in essential thrombocythemia
por: Guglielmelli, Paola, et al.
Publicado: (2021)

An earthworm protease cleaving serum fibronectin and decreasing HBeAg in HepG2.2.15 cells
por: Wang, Xue-Qing, et al.
Publicado: (2008)

Hydroxyurea Induced Perimalleolar Ulcers
por: Saravu, Kavitha, et al.
Publicado: (2006)

Mutagenic and Genotoxic Effect of Hydroxyurea
por: Santos, Jean L., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_8k74uejs3memhjdk3tmv8i15p8